Boston Pharmaceuticals, a portfolio company of B-Flexion, agreed to sell its lead asset, efimosfermin alfa, a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease, to GSK for up to $2 billion in cash, of which $1.2 billion will be paid upfront with potential for additional success-based milestone payments totaling $800 million.
Boston Pharmaceuticals is a clinical-stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases. B-Flexion is a private investment firm that manages the combined funds and investments associated with the Bertarelli family.
The S&C team representing B-Flexion includes Matt Hurd, Mimi Wu, Julia Liu and Alton Mathew, with valuable assistance from Jeremy Kutner. Jeannette Bander and Rebecca Rabinowitz are advising on executive compensation matters. Rachel Yu, KJ Lim and Jane Ninivaggi are advising on intellectual property matters. Tessa Lee, Stephen Profeta and Joel Forsstrom are advising on tax matters. Renata Hesse, Samantha Hynes, Julian Keeley and Nick Britton are advising on antitrust matters. Brad Smith, Clea McClellan and Shane Palmer are advising on HSR matters.